271 results on '"Van Gils, C.H."'
Search Results
2. Colorectal cancer follow-up after surgical resection since the COVID-19 pandemic: first steps towards out-of-hospital follow-up?
- Author
-
Siesling, S., van Hoeve, J.C., Merkx, M.A.W., de Wit, N.J., Helsper, C.W., Dingemans, I., Nagtegaal, I.D., Saathof, R., van Gils, C.H., van Weert, H.C.P.M., Verheij, M., Swartjes, H., Voigt, K.R., Wullaert, L., Meijer, J., van Erning, F.N., Verhoef, C., Grünhagen, D.J., Vissers, P.A.J., and de Wilt, J.H.W.
- Published
- 2024
- Full Text
- View/download PDF
3. Population-based impact of COVID-19 on incidence, treatment, and survival of patients with pancreatic cancer
- Author
-
Siesling, S., van Hoeve, J.C., Merkx, M.A.W., de Wit, N.J., Helsper, C.W., Dingemans, I., Nagtegaal, I.D., van der Schaaf, M., van Gils, C.H., van Weert, H.C.P.M., Verheij, M., Graus, Merlijn U.J.E., de Hingh, Ignace H.J.T., Besselink, Marc G., Bruno, Marco J., Wilmink, Johanna W., de Meijer, Vincent E., van Velthuysen, Marie-Louise F., Valkenburg-van Iersel, Liselot B.J., van der Geest, Lydia G.M., and de Vos-Geelen, Judith
- Published
- 2023
- Full Text
- View/download PDF
4. Sentinel node biopsy in patients with melanoma improves the accuracy of staging when added to clinicopathological features of the primary tumor
- Author
-
El Sharouni, M.-A., Stodell, M.D., Ahmed, T., Suijkerbuijk, K.P.M., Cust, A.E., Witkamp, A.J., Sigurdsson, V., van Diest, P.J., Scolyer, R.A., Thompson, J.F., van Gils, C.H., and Lo, S.N.
- Published
- 2021
- Full Text
- View/download PDF
5. The influence of socioeconomic status and ethnicity on adjuvant systemic treatment guideline adherence for early-stage breast cancer in the Netherlands
- Author
-
Kuijer, A., Verloop, J., Visser, O., Sonke, G., Jager, A., van Gils, C.H., van Dalen, T., and Elias, S.G.
- Published
- 2017
- Full Text
- View/download PDF
6. Population-based impact of COVID-19 on incidence, treatment, and survival of patients with pancreatic cancer
- Author
-
Graus, Merlijn U.J.E., primary, de Hingh, Ignace H.J.T., additional, Besselink, Marc G., additional, Bruno, Marco J., additional, Wilmink, Johanna W., additional, de Meijer, Vincent E., additional, van Velthuysen, Marie-Louise F., additional, Valkenburg-van Iersel, Liselot B.J., additional, van der Geest, Lydia G.M., additional, de Vos-Geelen, Judith, additional, Siesling, S., additional, van Hoeve, J.C., additional, Merkx, M.A.W., additional, de Wit, N.J., additional, Helsper, C.W., additional, Dingemans, I., additional, Nagtegaal, I.D., additional, van der Schaaf, M., additional, van Gils, C.H., additional, van Weert, H.C.P.M., additional, and Verheij, M., additional
- Published
- 2023
- Full Text
- View/download PDF
7. Reasons for (non)participation in supplemental population-based MRI breast screening for women with extremely dense breasts
- Author
-
de Lange, S.V., Bakker, M.F., Monninkhof, E.M., Peeters, P.H.M., de Koekkoek-Doll, P.K., Mann, R.M., Rutten, M.J.C.M., Bisschops, R.H.C., Veltman, J., Duvivier, K.M., Lobbes, M.B.I., de Koning, H.J., Karssemeijer, N., Pijnappel, R.M., Veldhuis, W.B., and van Gils, C.H.
- Published
- 2018
- Full Text
- View/download PDF
8. Population-based estimates of overtreatment with adjuvant systemic therapy in early breast cancer patients with data from the Netherlands and the USA
- Author
-
Ragusi, M.A.A., van der Velden, B.H.M., van Maaren, M.C., van der Wall, E., van Gils, C.H., Pijnappel, R.M., Gilhuijs, K.G.A., Elias, S.G., Ragusi, M.A.A., van der Velden, B.H.M., van Maaren, M.C., van der Wall, E., van Gils, C.H., Pijnappel, R.M., Gilhuijs, K.G.A., and Elias, S.G.
- Abstract
Purpose: Although adjuvant systemic therapy (AST) helps increase breast cancer-specific survival (BCSS), there is a growing concern for overtreatment. By estimating the expected BCSS of AST using PREDICT, this study aims to quantify the number of patients treated with AST without benefit to provide estimates of overtreatment. Methods: Data of all non-metastatic unilateral breast cancer patients diagnosed in 2015 were retrieved from cancer registries from The Netherlands and the USA. The PREDICT tool was used to estimate AST survival benefit. Overtreatment was defined as the proportion of patients that would have survived regardless of or died despite AST within 10 years. Three scenarios were evaluated: actual treatment, and recommendations by the Dutch or USA guidelines. Results: 59.5% of Dutch patients were treated with AST. 6.4% (interquartile interval [IQI] = 2.5, 8.2%) was expected to survive at least 10 years due to AST, leaving 93.6% (IQI = 91.8, 97.5%) without AST benefit (overtreatment). The lowest expected amount of overtreatment was in the targeted and chemotherapy subgroup, with 86.5% (IQI = 83.4, 89.6%) overtreatment, and highest in the only endocrine treatment subgroup, with 96.7% (IQI = 96.0, 98.1%) overtreatment. Similar results were obtained using data from the USA, and guideline recommendations. Conclusion: Based on PREDICT, AST prevents 10-year breast cancer death in 6.4% of the patients treated with AST. Consequently, AST yields no survival benefit to many treated patients. Especially improved personalization of endocrine therapy is relevant, as this therapy is widely used and is associated with the highest amount of overtreatment.
- Published
- 2022
9. Biomarkers of folate and vitamin B12 and breast cancer risk: report from the EPIC cohort
- Author
-
Matejcic, M., de Batlle, J., Ricci, C., Biessy, C., Perrier, F., Huybrechts, I., Weiderpass, E., BoutronRuault, M.C., Cadeau, C., His, M., Cox, D.G., Boeing, H., Fortner, R.T., Kaaks, R., Lagiou, P., Trichopoulou, A., Benetou, V., Tumino, R., Panico, S., Sieri, S., Palli, D., Ricceri, F., BuenodeMesquita, H.B(as), Skeie, G., Amiano, P., Sánchez, M.J., Chirlaque, M.D., Barricarte, A., Quirós, J.R., Buckland, G., van Gils, C.H., Peeters, P.H., Key, T.J., Riboli, E., Gylling, B., ZeleniuchJacquotte, A., Gunter, M.J., Romieu, I., and Chajès, V.
- Published
- 2017
- Full Text
- View/download PDF
10. Long-term exposure to fine particle elemental components and lung cancer incidence in the ELAPSE pooled cohort
- Author
-
Hvidtfeldt, U.A. Chen, J. Andersen, Z.J. Atkinson, R. Bauwelinck, M. Bellander, T. Brandt, J. Brunekreef, B. Cesaroni, G. Concin, H. Fecht, D. Forastiere, F. van Gils, C.H. Gulliver, J. Hertel, O. Hoek, G. Hoffmann, B. de Hoogh, K. Janssen, N. Jørgensen, J.T. Katsouyanni, K. Jöckel, K.-H. Ketzel, M. Klompmaker, J.O. Lang, A. Leander, K. Liu, S. Ljungman, P.L.S. Magnusson, P.K.E. Mehta, A.J. Nagel, G. Oftedal, B. Pershagen, G. Peter, R.S. Peters, A. Renzi, M. Rizzuto, D. Rodopoulou, S. Samoli, E. Schwarze, P.E. Severi, G. Sigsgaard, T. Stafoggia, M. Strak, M. Vienneau, D. Weinmayr, G. Wolf, K. Raaschou-Nielsen, O.
- Subjects
complex mixtures - Abstract
Background: An association between long-term exposure to fine particulate matter (PM2.5) and lung cancer has been established in previous studies. PM2.5 is a complex mixture of chemical components from various sources and little is known about whether certain components contribute specifically to the associated lung cancer risk. The present study builds on recent findings from the “Effects of Low-level Air Pollution: A Study in Europe” (ELAPSE) collaboration and addresses the potential association between specific elemental components of PM2.5 and lung cancer incidence. Methods: We pooled seven cohorts from across Europe and assigned exposure estimates for eight components of PM2.5 representing non-tail pipe emissions (copper (Cu), iron (Fe), and zinc (Zn)), long-range transport (sulfur (S)), oil burning/industry emissions (nickel (Ni), vanadium (V)), crustal material (silicon (Si)), and biomass burning (potassium (K)) to cohort participants’ baseline residential address based on 100 m by 100 m grids from newly developed hybrid models combining air pollution monitoring, land use data, satellite observations, and dispersion model estimates. We applied stratified Cox proportional hazards models, adjusting for potential confounders (age, sex, calendar year, marital status, smoking, body mass index, employment status, and neighborhood-level socio-economic status). Results: The pooled study population comprised 306,550 individuals with 3916 incident lung cancer events during 5,541,672 person-years of follow-up. We observed a positive association between exposure to all eight components and lung cancer incidence, with adjusted HRs of 1.10 (95% CI 1.05, 1.16) per 50 ng/m3 PM2.5 K, 1.09 (95% CI 1.02, 1.15) per 1 ng/m3 PM2.5 Ni, 1.22 (95% CI 1.11, 1.35) per 200 ng/m3 PM2.5 S, and 1.07 (95% CI 1.02, 1.12) per 200 ng/m3 PM2.5 V. Effect estimates were largely unaffected by adjustment for nitrogen dioxide (NO2). After adjustment for PM2.5 mass, effect estimates of K, Ni, S, and V were slightly attenuated, whereas effect estimates of Cu, Si, Fe, and Zn became null or negative. Conclusions: Our results point towards an increased risk of lung cancer in connection with sources of combustion particles from oil and biomass burning and secondary inorganic aerosols rather than non-exhaust traffic emissions. Specific limit values or guidelines targeting these specific PM2.5 components may prove helpful in future lung cancer prevention strategies. © 2020 Elsevier Inc.
- Published
- 2021
11. Methylation is less abundant in BRCA1-associated compared with sporadic breast cancer
- Author
-
Suijkerbuijk, K.P.M., Fackler, M.J., Sukumar, S., van Gils, C.H., van Laar, T., van der Wall, E., Vooijs, M., and van Diest, P.J.
- Published
- 2008
- Full Text
- View/download PDF
12. Dietary intake of the water-soluble vitamins B1, B2, B6, B12 and C in 10 countries in the European Prospective Investigation into Cancer and Nutrition
- Author
-
Olsen, A., Halkjaer, J., van Gils, C.H., Buijsse, B., Verhagen, H., Jenab, M., Boutron-Ruault, M.C., Ericson, U., Ocke, M.C., Peeters, P.H.M., Touvier, M., Niravong, M., Waaseth, M., Skeie, G., Khaw, K.T., Travis, R., Ferrari, P., Sanchez, M.J., Agudo, A., Overvad, K., Linseisen, J., Weikert, C., Sacerdote, C., Evangelista, A., Zylis, D., Tsiotas, K., Manjer, J., van Guelpen, B., Riboli, E., Slimani, N., and Bingham, S.
- Subjects
Oncology, Experimental -- Health aspects ,Vitamin C -- Health aspects -- Research ,Vitamin B -- Health aspects -- Research ,Cancer -- Research ,Vitamin B in human nutrition -- Research -- Health aspects ,Vitamin B complex -- Health aspects -- Research ,Recommended daily allowances -- Research -- Health aspects ,Food/cooking/nutrition ,Health - Abstract
Objectives: To describe the intake of vitamins thiamine (B1), riboflavin (B2), B6 (pyridoxine), B12 (cobalamine) and C (ascorbic acid) and their food sources among 27 centres in 10 countries participating in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Methods: Between 1995 and 2000, 36 034 persons aged between 35 and 74 years were administered a standardized 24-h dietary recall using a computerized interview software programme (EPIC-SOFT). Intakes of the four B vitamins and vitamin C were estimated using the standardized EPIC Nutrient Database (ENDB). Mean intakes were adjusted for age and weighted by season and day of recall. Results: Intake of B vitamins did not vary considerably between centres, except in the UK health-conscious cohort, in which substantially higher intakes of thiamine and lower intakes of vitamin B12 were reported compared with other centres. Overall, meat was the most important contributor to the B vitamins in all centres except in the UK health-conscious group. Vitamin C showed a clear geographical gradient, with higher intakes in the southern centres as compared with the northern ones; this was more pronounced in men than in women. Vegetables and fruits were major contributors to vitamin C in all centres, but juices and potatoes were also important sources in the northern centres. Conclusions: This study showed no major differences across centres in the mean intakes of B vitamins (thiamine, riboflavin, B6, B12), whereas a tendency towards a north-south gradient was observed for vitamin C. doi: 10.1038/ejcn.2009.78 Keywords: water-soluble vitamins; 24-h dietary recall; standardization; ENDB; EPIC; Europe, Introduction The B vitamins, together with vitamin C, constitute the water-soluble group of vitamins. Classic syndromes caused by a deficiency of water-soluble vitamins, such as scurvy (vitamin C) and beriberi [...]
- Published
- 2009
- Full Text
- View/download PDF
13. Predicting sentinel node positivity in patients with melanoma: external validation of a risk‐prediction calculator (the Melanoma Institute Australia nomogram) using a large European population‐based patient cohort*
- Author
-
El Sharouni, M.A., primary, Varey, A.H.R., additional, Witkamp, A.J., additional, Ahmed, T., additional, Sigurdsson, V., additional, van Diest, P.J., additional, Scolyer, R.A., additional, Thompson, J.F., additional, Lo, S.N., additional, and van Gils, C.H., additional
- Published
- 2021
- Full Text
- View/download PDF
14. Healthy lifestyle and the risk of pancreatic cancer in the EPIC study
- Author
-
Naudin, S. Viallon, V. Hashim, D. Freisling, H. Jenab, M. Weiderpass, E. Perrier, F. McKenzie, F. Bueno-de-Mesquita, H.B. Olsen, A. Tjønneland, A. Dahm, C.C. Overvad, K. Mancini, F.R. Rebours, V. Boutron-Ruault, M.-C. Katzke, V. Kaaks, R. Bergmann, M. Boeing, H. Peppa, E. Karakatsani, A. Trichopoulou, A. Pala, V. Masala, G. Panico, S. Tumino, R. Sacerdote, C. May, A.M. van Gils, C.H. Rylander, C. Borch, K.B. Chirlaque López, M.D. Sánchez, M.-J. Ardanaz, E. Quirós, J.R. Amiano Exezarreta, P. Sund, M. Drake, I. Regnér, S. Travis, R.C. Wareham, N. Aune, D. Riboli, E. Gunter, M.J. Duell, E.J. Brennan, P. Ferrari, P.
- Abstract
Pancreatic cancer (PC) is a highly fatal cancer with currently limited opportunities for early detection and effective treatment. Modifiable factors may offer pathways for primary prevention. In this study, the association between the Healthy Lifestyle Index (HLI) and PC risk was examined. Within the European Prospective Investigation into Cancer and Nutrition cohort, 1113 incident PC (57% women) were diagnosed from 400,577 participants followed-up for 15 years (median). HLI scores combined smoking, alcohol intake, dietary exposure, physical activity and, in turn, overall and central adiposity using BMI (HLIBMI) and waist-to-hip ratio (WHR, HLIWHR), respectively. High values of HLI indicate adherence to healthy behaviors. Cox proportional hazard models with age as primary time variable were used to estimate PC hazard ratios (HR) and 95% confidence intervals (CI). Sensitivity analyses were performed by excluding, in turn, each factor from the HLI score. Population attributable fractions (PAF) were estimated assuming participants’ shift to healthier lifestyles. The HRs for a one-standard deviation increment of HLIBMI and HLIWHR were 0.84 (95% CI: 0.79, 0.89; ptrend = 4.3e−09) and 0.77 (0.72, 0.82; ptrend = 1.7e−15), respectively. Exclusions of smoking from HLIWHR resulted in HRs of 0.88 (0.82, 0.94; ptrend = 4.9e−04). The overall PAF estimate was 19% (95% CI: 11%, 26%), and 14% (6%, 21%) when smoking was removed from the score. Adherence to a healthy lifestyle was inversely associated with PC risk, beyond the beneficial role of smoking avoidance. Public health measures targeting compliance with healthy lifestyles may have an impact on PC incidence. © 2019, Springer Nature B.V.
- Published
- 2020
15. Prediagnostic Plasma Bile Acid Levels and Colon Cancer Risk: A Prospective Study
- Author
-
Kühn, T. Stepien, M. López-Nogueroles, M. Damms-Machado, A. Sookthai, D. Johnson, T. Roca, M. Hüsing, A. Maldonado, S.G. Cross, A.J. Murphy, N. Freisling, H. Rinaldi, S. Scalbert, A. Fedirko, V. Severi, G. Boutron-Ruault, M.-C. Mancini, F.R. Sowah, S.A. Boeing, H. Jakszyn, P. Sánchez, M.J. Merino, S. Colorado-Yohar, S. Barricarte, A. Khaw, K.T. Schmidt, J.A. Perez-Cornago, A. Trichopoulou, A. Karakatsani, A. Thriskos, P. Palli, D. Agnoli, C. Tumino, R. Sacerdote, C. Panico, S. Bueno-De-Mesquita, B. Van Gils, C.H. Heath, A.K. Gunter, M.J. Riboli, E. Lahoz, A. Jenab, M. Kaaks, R.
- Abstract
Background: Bile acids have been proposed to promote colon carcinogenesis. However, there are limited prospective data on circulating bile acid levels and colon cancer risk in humans. Methods: Associations between prediagnostic plasma levels of 17 primary, secondary, and tertiary bile acid metabolites (conjugated and unconjugated) and colon cancer risk were evaluated in a nested case-control study within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Bile acid levels were quantified by tandem mass spectrometry in samples from 569 incident colon cancer cases and 569 matched controls. Multivariable logistic regression analyses were used to estimate odds ratios (ORs) for colon cancer risk across quartiles of bile acid concentrations. Results: Positive associations were observed between colon cancer risk and plasma levels of seven conjugated bile acid metabolites: the primary bile acids glycocholic acid (ORquartile 4 vs quartile 1= 2.22, 95% confidence interval [CI] = 1.52 to 3.26), taurocholic acid (OR = 1.78, 95% CI = 1.23 to 2.58), glycochenodeoxycholic acid (OR = 1.68, 95% CI = 1.13 to 2.48), taurochenodeoxycholic acid (OR = 1.62, 95% CI = 1.11 to 2.36), and glycohyocholic acid (OR = 1.65, 95% CI = 1.13 to 2.40), and the secondary bile acids glycodeoxycholic acid (OR = 1.68, 95% CI = 1.12 to 2.54) and taurodeoxycholic acid (OR = 1.54, 95% CI = 1.02 to 2.31). By contrast, unconjugated bile acids and tertiary bile acids were not associated with risk. Conclusions: This prospective study showed that prediagnostic levels of certain conjugated primary and secondary bile acids were positively associated with risk of colon cancer. Our findings support experimental data to suggest that a high bile acid load is colon cancer promotive. © 2020 The Author(s) 2019. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.
- Published
- 2020
16. Menstrual factors, reproductive history, hormone use, and urothelial carcinoma risk: a prospective study in the EPIC cohort
- Author
-
Lujan-Barroso, L. Botteri, E. Caini, S. Ljungberg, B.F. Roswall, N. Tjønneland, A. Bueno-De-Mesquita, B. Gram, I.T. Tumino, R. Kiemeney, L.A. Liedberg, F. Stocks, T. Gunter, M.J. Murphy, N. Cervenka, I. Fournier, A. Kvaskoff, M. Haggstrom, C. Overvad, K. Lund, E. Waaseth, M. Fortner, R.T. Kuhn, T. Menendez, V. Sanchez, M.-J. Santiuste, C. Perez-Cornago, A. Zamora-Ros, R. Cross, A.J. Trichopoulou, A. Karakatsani, A. Peppa, E. Palli, D. Krogh, V. Sciannameo, V. Mattiello, A. Panico, S. van Gils, C.H. Charlotte Onland-Moret, N. Barricarte, A. Amiano, P. Khaw, K.-T. Boeing, H. Weiderpass, E. Duell, E.J.
- Abstract
Background: Urothelial carcinoma is the predominant (95%) bladder cancer subtype in industrialized nations. Animal and epidemiologic human studies suggest that hormonal factors may influence urothelial carcinoma risk. Methods: We used an analytic cohort of 333,919 women from the European Prospective Investigation into Cancer and Nutrition Cohort. Associations between hormonal factors and incident urothelial carcinoma (overall and by tumor grade, tumor aggressiveness, and non–muscle-invasive urothelial carcinoma) risk were evaluated using Cox proportional hazards models. Results: During a mean of 15 years of follow-up, 529 women developed urothelial carcinoma. In a model including number of full-term pregnancies (FTP), menopausal status, and menopausal hormone therapy (MHT), number of FTP was inversely associated with urothelial carcinoma risk (HR≥5vs1 ¼ 0.48; 0.25–0.90; Ptrend in parous women ¼ 0.010) and MHT use (compared with nonuse) was positively associated with urothelial carcinoma risk (HR ¼ 1.27; 1.03–1.57), but no dose response by years of MHT use was observed. No modification of HRs by smoking status was observed. Finally, sensitivity analyses in never smokers showed similar HR patterns for the number of FTP, while no association between MHT use and urothelial carcinoma risk was observed. Association between MHT use and urothelial carcinoma risk remained significant only in current smokers. No heterogeneity of the risk estimations in the final model was observed by tumor aggressiveness or by tumor grade. A positive association between MTH use and non–muscle-invasive urothelial carcinoma risk was observed. Conclusions: Our results support that increasing the number of FTP may reduce urothelial carcinoma risk. Impact: More detailed studies on parity are needed to understand the possible effects of perinatal hormone changes in urothelial cells. © 2020 American Association for Cancer Research.
- Published
- 2020
17. Blood pressure and risk of cancer in the European Prospective Investigation into Cancer and Nutrition
- Author
-
Christakoudi, S. Kakourou, A. Markozannes, G. Tzoulaki, I. Weiderpass, E. Brennan, P. Gunter, M. Dahm, C.C. Overvad, K. Olsen, A. Tjønneland, A. Boutron-Ruault, M.-C. Madika, A.-L. Severi, G. Katzke, V. Kühn, T. Bergmann, M.M. Boeing, H. Karakatsani, A. Martimianaki, G. Thriskos, P. Masala, G. Sieri, S. Panico, S. Tumino, R. Ricceri, F. Agudo, A. Redondo-Sánchez, D. Colorado-Yohar, S.M. Mokoroa, O. Melander, O. Stocks, T. Häggström, C. Harlid, S. Bueno-de-Mesquita, B. van Gils, C.H. Vermeulen, R.C.H. Khaw, K.-T. Wareham, N.J. Tong, T.Y.N. Freisling, H. Johansson, M. Lennon, H. Aune, D. Riboli, E. Trichopoulos, D. Trichopoulou, A. Tsilidis, K.K.
- Abstract
Several studies have reported associations of hypertension with cancer, but not all results were conclusive. We examined the association of systolic (SBP) and diastolic (DBP) blood pressure with the development of incident cancer at all anatomical sites in the European Prospective Investigation into Cancer and Nutrition (EPIC). Hazard ratios (HRs) (95% confidence intervals) were estimated using multivariable Cox proportional hazards models, stratified by EPIC-participating center and age at recruitment, and adjusted for sex, education, smoking, body mass index, physical activity, diabetes and dietary (in women also reproductive) factors. The study included 307,318 men and women, with an average follow-up of 13.7 (standard deviation 4.4) years and 39,298 incident cancers. We confirmed the expected positive association with renal cell carcinoma: HR = 1.12 (1.08–1.17) per 10 mm Hg higher SBP and HR = 1.23 (1.14–1.32) for DBP. We additionally found positive associations for esophageal squamous cell carcinoma (SCC): HR = 1.16 (1.07–1.26) (SBP), HR = 1.31 (1.13–1.51) (DBP), weaker for head and neck cancers: HR = 1.08 (1.04–1.12) (SBP), HR = 1.09 (1.01–1.17) (DBP) and, similarly, for skin SCC, colon cancer, postmenopausal breast cancer and uterine adenocarcinoma (AC), but not for esophageal AC, lung SCC, lung AC or uterine endometroid cancer. We observed weak inverse associations of SBP with cervical SCC: HR = 0.91 (0.82–1.00) and lymphomas: HR = 0.97 (0.93–1.00). There were no consistent associations with cancers in other locations. Our results are largely compatible with published studies and support weak associations of blood pressure with cancers in specific locations and morphologies. © 2019 UICC
- Published
- 2020
18. Blood pressure and risk of cancer in the European Prospective Investigation into Cancer and Nutrition
- Author
-
Christakoudi, S., Kakourou, A., Markozannes, G., Tzoulaki, I., Weiderpass, E., Brennan, P., Gunter, M., Dahm, C.C., Overvad, K., Olsen, A., Tjønneland, A., Boutron-Ruault, M.-C., Madika, A.-L., Severi, G., Katzke, V., Kühn, T., Bergmann, M.M., Boeing, H., Karakatsani, A., Martimianaki, G., Thriskos, P., Masala, G., Sieri, S., Panico, S., Tumino, R., Ricceri, F., Agudo, A., Redondo-Sánchez, D., Colorado-Yohar, S.M., Mokoroa, O., Melander, O., Stocks, T., Häggström, C., Harlid, S., Bueno-de-Mesquita, B., van Gils, C.H., Vermeulen, R.C.H., Khaw, K.-T., Wareham, N.J., Tong, T.Y.N., Freisling, H., Johansson, M., Lennon, H., Aune, D., Riboli, E., Trichopoulos, D., Trichopoulou, A., Tsilidis, K.K., Christakoudi, S., Kakourou, A., Markozannes, G., Tzoulaki, I., Weiderpass, E., Brennan, P., Gunter, M., Dahm, C.C., Overvad, K., Olsen, A., Tjønneland, A., Boutron-Ruault, M.-C., Madika, A.-L., Severi, G., Katzke, V., Kühn, T., Bergmann, M.M., Boeing, H., Karakatsani, A., Martimianaki, G., Thriskos, P., Masala, G., Sieri, S., Panico, S., Tumino, R., Ricceri, F., Agudo, A., Redondo-Sánchez, D., Colorado-Yohar, S.M., Mokoroa, O., Melander, O., Stocks, T., Häggström, C., Harlid, S., Bueno-de-Mesquita, B., van Gils, C.H., Vermeulen, R.C.H., Khaw, K.-T., Wareham, N.J., Tong, T.Y.N., Freisling, H., Johansson, M., Lennon, H., Aune, D., Riboli, E., Trichopoulos, D., Trichopoulou, A., and Tsilidis, K.K.
- Abstract
Several studies have reported associations of hypertension with cancer, but not all results were conclusive. We examined the association of systolic (SBP) and diastolic (DBP) blood pressure with the development of incident cancer at all anatomical sites in the European Prospective Investigation into Cancer and Nutrition (EPIC). Hazard ratios (HRs) (95% confidence intervals) were estimated using multivariable Cox proportional hazards models, stratified by EPIC-participating center and age at recruitment, and adjusted for sex, education, smoking, body mass index, physical activity, diabetes and dietary (in women also reproductive) factors. The study included 307,318 men and women, with an average follow-up of 13.7 (standard deviation 4.4) years and 39,298 incident cancers. We confirmed the expected positive association with renal cell carcinoma: HR = 1.12 (1.08–1.17) per 10 mm Hg higher SBP and HR = 1.23 (1.14–1.32) for DBP. We additionally found positive associations for esophageal squamous cell carcinoma (SCC): HR = 1.16 (1.07–1.26) (SBP), HR = 1.31 (1.13–1.51) (DBP), weaker for head and neck cancers: HR = 1.08 (1.04–1.12) (SBP), HR = 1.09 (1.01–1.17) (DBP) and, similarly, for skin SCC, colon cancer, postmenopausal breast cancer and uterine adenocarcinoma (AC), but not for esophageal AC, lung SCC, lung AC or uterine endometroid cancer. We observed weak inverse associations of SBP with cervical SCC: HR = 0.91 (0.82–1.00) and lymphomas: HR = 0.97 (0.93–1.00). There were no consistent associations with cancers in other locations. Our results are largely compatible with published studies and support weak associations of blood pressure with cancers in specific locations and morphologies.
- Published
- 2020
19. Blood pressure and risk of cancer in the European Prospective Investigation into Cancer and Nutrition
- Author
-
IRAS OH Epidemiology Chemical Agents, dIRAS RA-2, Christakoudi, S., Kakourou, A., Markozannes, G., Tzoulaki, I., Weiderpass, E., Brennan, P., Gunter, M., Dahm, C.C., Overvad, K., Olsen, A., Tjønneland, A., Boutron-Ruault, M.-C., Madika, A.-L., Severi, G., Katzke, V., Kühn, T., Bergmann, M.M., Boeing, H., Karakatsani, A., Martimianaki, G., Thriskos, P., Masala, G., Sieri, S., Panico, S., Tumino, R., Ricceri, F., Agudo, A., Redondo-Sánchez, D., Colorado-Yohar, S.M., Mokoroa, O., Melander, O., Stocks, T., Häggström, C., Harlid, S., Bueno-de-Mesquita, B., van Gils, C.H., Vermeulen, R.C.H., Khaw, K.-T., Wareham, N.J., Tong, T.Y.N., Freisling, H., Johansson, M., Lennon, H., Aune, D., Riboli, E., Trichopoulos, D., Trichopoulou, A., Tsilidis, K.K., IRAS OH Epidemiology Chemical Agents, dIRAS RA-2, Christakoudi, S., Kakourou, A., Markozannes, G., Tzoulaki, I., Weiderpass, E., Brennan, P., Gunter, M., Dahm, C.C., Overvad, K., Olsen, A., Tjønneland, A., Boutron-Ruault, M.-C., Madika, A.-L., Severi, G., Katzke, V., Kühn, T., Bergmann, M.M., Boeing, H., Karakatsani, A., Martimianaki, G., Thriskos, P., Masala, G., Sieri, S., Panico, S., Tumino, R., Ricceri, F., Agudo, A., Redondo-Sánchez, D., Colorado-Yohar, S.M., Mokoroa, O., Melander, O., Stocks, T., Häggström, C., Harlid, S., Bueno-de-Mesquita, B., van Gils, C.H., Vermeulen, R.C.H., Khaw, K.-T., Wareham, N.J., Tong, T.Y.N., Freisling, H., Johansson, M., Lennon, H., Aune, D., Riboli, E., Trichopoulos, D., Trichopoulou, A., and Tsilidis, K.K.
- Published
- 2020
20. Heritable Aspects of Dysplastic Breast Glandular Tissue (DY)
- Author
-
Haars, G., van Noord, P.A.H., van Gils, C.H., Peeters, P.H.M., and Grobbee, D.E.
- Published
- 2004
- Full Text
- View/download PDF
21. Antibody responses to Fusobacterium nucleatum Proteins in prediagnostic blood samples are not associated with risk of developing colorectal cancer
- Author
-
Butt, J. Jenab, M. Pawlita, M. Overvad, K. Tjonneland, A. Olsen, A. Boutron-Ruault, M.-C. Carbonnel, F. Mancini, F.R. Kaaks, R. Kuhn, T. Boeing, H. Trichopoulou, A. Karakatsani, A. Palli, D. Pala, V.M. Tumino, R. Sacerdote, C. Panico, S. Bueno-De-Mesquita, B. Van Gils, C.H. Vermeulen, R.C.H. Weiderpass, E. Quiros, J.R. Duell, E.J. Sanchez, M.-J. Dorronsoro, M. Huerta, J.M. Ardanaz, E. Van Guelpen, B. Harlid, S. Perez-Cornago, A. Gunter, M.J. Murphy, N. Freisling, H. Aune, D. Waterboer, T. Hughes, D.J.
- Subjects
stomatognathic diseases ,stomatognathic system - Abstract
Background: There is a lack of prospective data on the potential association of Fusobacterium nucleatum (F. nucleatum) and colorectal cancer risk. In this study, we assessed whether antibody responses to F. nucleatum are associated with colorectal cancer risk in prediagnostic serum samples in the European Prospective Investigation into Nutrition and Cancer (EPIC) cohort. Methods: We applied a multiplex serology assay to simultaneously measure antibody responses to 11 F. nucleatum antigens in prediagnostic serum samples from 485 colorectal cancer cases and 485 matched controls. Conditional logistic regression models were used to estimate odds ratios (ORs) and 95% confidence intervals (CI). Results: We observed neither a statistically significant colorectal cancer risk association for antibodies to individual F. nucleatum proteins nor for combined positivity to any of the 11 proteins (OR, 0.81; 95% CI, 0.62–1.06). Conclusions: Antibody responses to F. nucleatum proteins in prediagnostic serum samples from a subset of colorectal cancer cases and matched controls within the EPIC study were not associated with colorectal cancer risk. Impact: Our findings in prospectively ascertained serum samples contradict the existing literature on the association of F. nucleatum with colorectal cancer risk. Future prospective studies, specifically detecting F. nucleatum in stool or tissue biopsies, are needed to complement our findings. © 2019 American Association for Cancer Research.
- Published
- 2019
22. Reproductive and Lifestyle Factors and Circulating sRANKL and OPG Concentrations in Women: Results from the EPIC Cohort
- Author
-
Sarink, D. Yang, J. Johnson, T. Chang-Claude, J. Overvad, K. Olsen, A. Tjønneland, A. Fournier, A. Mancini, F.R. Kvaskoff, M. Boeing, H. Trichopoulou, A. Karakatsani, A. Valanou, E. Agnoli, C. Sacerdote, C. Masala, G. Mattiello, A. Tumino, R. Van Gils, C.H. Skeie, G. Gram, I.T. Weiderpass, E. Lujan-Barroso, L. Petrova, D. Santiuste, C. Quirós, J.R. Barricarte, A. Amiano, P. Travis, R.C. Gunter, M. Dossus, L. Christakoudi, S. Kaaks, R. Fortner, R.T.
- Subjects
musculoskeletal diseases - Abstract
Background: Except for a documented increase in osteoprotegerin (OPG) concentrations with older age, data on determinants of soluble Receptor Activator of Nuclear Factor kB (sRANKL) and OPG concentrations in women are limited. We evaluated reproductive and lifestyle factors as potential sources of variation in circulating sRANKL and OPG concentrations in pre- and postmenopausal women. Methods: This study includes 2,016 controls [n = 1,552 (76%) postmenopausal, n = 757 (38%) using postmenopausal hormone therapy (PMH)] from a breast cancer case-control study nested in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Serum sRANKL was measured using an ELISA and serum OPG using an electrochemiluminescent assay. Generalized linear models were used to evaluate associations between these analytes and reproductive and lifestyle factors. Results: Older age at blood collection was associated with lower sRANKL concentrations in postmenopausal women (Ptrend < 0.03) and higher OPG concentrations in all women (Ptrend < 0.01). Longer duration of oral contraceptive use among premenopausal women and postmenopausal PMH users was associated with higher OPG (Ptrend < 0.04). In postmenopausal non-PMH users, sRANKL concentrations were lower with longer duration of oral contraceptive use and current (vs. never) smoking (P < 0.01). sRANKL concentrations were higher among women with higher BMI (Ptrend < 0.01). The evaluated factors accounted for 12% of the variation in sRANKL concentrations and 21% of the variation in OPG concentrations. Conclusions: Circulating sRANKL and OPG concentrations are minimally impacted by hormone-related factors in pre- and postmenopausal women. Impact: This study suggests circulating concentrations of sRANKL and OPG are unlikely to be strongly modified by hormone-related reproductive and lifestyle factors. © 2019 American Association for Cancer Research.
- Published
- 2019
23. Prospective analysis of circulating metabolites and breast cancer in EPIC
- Author
-
His, M. Viallon, V. Dossus, L. Gicquiau, A. Achaintre, D. Scalbert, A. Ferrari, P. Romieu, I. Onland-Moret, N.C. Weiderpass, E. Dahm, C.C. Overvad, K. Olsen, A. Tjønneland, A. Fournier, A. Rothwell, J.A. Severi, G. Kühn, T. Fortner, R.T. Boeing, H. Trichopoulou, A. Karakatsani, A. Martimianaki, G. Masala, G. Sieri, S. Tumino, R. Vineis, P. Panico, S. Van Gils, C.H. Nøst, T.H. Sandanger, T.M. Skeie, G. Quirós, J.R. Agudo, A. Sánchez, M.-J. Amiano, P. Huerta, J.M. Ardanaz, E. Schmidt, J.A. Travis, R.C. Riboli, E. Tsilidis, K.K. Christakoudi, S. Gunter, M.J. Rinaldi, S.
- Abstract
Background: Metabolomics is a promising molecular tool to identify novel etiologic pathways leading to cancer. Using a targeted approach, we prospectively investigated the associations between metabolite concentrations in plasma and breast cancer risk. Methods: A nested case-control study was established within the European Prospective Investigation into Cancer cohort, which included 1624 first primary incident invasive breast cancer cases (with known estrogen and progesterone receptor and HER2 status) and 1624 matched controls. Metabolites (n = 127, acylcarnitines, amino acids, biogenic amines, glycerophospholipids, hexose, sphingolipids) were measured by mass spectrometry in pre-diagnostic plasma samples and tested for associations with breast cancer incidence using multivariable conditional logistic regression. Results: Among women not using hormones at baseline (n = 2248), and after control for multiple tests, concentrations of arginine (odds ratio [OR] per SD = 0.79, 95% confidence interval [CI] = 0.70-0.90), asparagine (OR = 0.83 (0.74-0.92)), and phosphatidylcholines (PCs) ae C36:3 (OR = 0.83 (0.76-0.90)), aa C36:3 (OR = 0.84 (0.77-0.93)), ae C34:2 (OR = 0.85 (0.78-0.94)), ae C36:2 (OR = 0.85 (0.78-0.88)), and ae C38:2 (OR = 0.84 (0.76-0.93)) were inversely associated with breast cancer risk, while the acylcarnitine C2 (OR = 1.23 (1.11-1.35)) was positively associated with disease risk. In the overall population, C2 (OR = 1.15 (1.06-1.24)) and PC ae C36:3 (OR = 0.88 (0.82-0.95)) were associated with risk of breast cancer, and these relationships did not differ by breast cancer subtype, age at diagnosis, fasting status, menopausal status, or adiposity. Conclusions: These findings point to potentially novel pathways and biomarkers of breast cancer development. Results warrant replication in other epidemiological studies. © 2019 The Author(s).
- Published
- 2019
24. Adherence to the World Cancer Research Fund/American Institute for Cancer Research cancer prevention recommendations and risk of in situ breast cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort
- Author
-
Karavasiloglou, N. Hüsing, A. Masala, G. Van Gils, C.H. Turzanski Fortner, R. Chang-Claude, J. Huybrechts, I. Weiderpass, E. Gunter, M. Arveux, P. Fournier, A. Kvaskoff, M. Tjønneland, A. Kyrø, C. Dahm, C.C. Vistisen, H.T. Bakker, M.F. Sánchez, M.-J. Chirlaque López, M.D. Santiuste, C. Ardanaz, E. Menéndez, V. Agudo, A. Trichopoulou, A. Karakatsani, A. La Vecchia, C. Peppa, E. Palli, D. Agnoli, C. Panico, S. Tumino, R. Sacerdote, C. Butt, S.T. Borgquist, S. Skeie, G. Schulze, M. Key, T. Khaw, K.-T. Tsilidis, K.K. Ellingjord-Dale, M. Riboli, E. Kaaks, R. Dossus, L. Rohrmann, S. Kühn, T.
- Abstract
Background: Even though in situ breast cancer (BCIS) accounts for a large proportion of the breast cancers diagnosed, few studies have investigated potential risk factors for BCIS. Their results suggest that some established risk factors for invasive breast cancer have a similar impact on BCIS risk, but large population-based studies on lifestyle factors and BCIS risk are lacking. Thus, we investigated the association between lifestyle and BCIS risk within the European Prospective Investigation into Cancer and Nutrition cohort. Methods: Lifestyle was operationalized by a score reflecting the adherence to the World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) cancer prevention recommendations. The recommendations utilized in these analyses were the ones pertinent to healthy body weight, physical activity, consumption of plant-based foods, energy-dense foods, red and processed meat, and sugary drinks and alcohol, as well as the recommendation on breastfeeding. Cox proportional hazards regression was used to assess the association between lifestyle score and BCIS risk. The results were presented as hazard ratios (HR) and corresponding 95% confidence intervals (CI). Results: After an overall median follow-up time of 14.9 years, 1277 BCIS cases were diagnosed. Greater adherence to the WCRF/AICR cancer prevention recommendations was not associated with BCIS risk (HR = 0.98, 95% CI 0.93-1.03; per one unit of increase; multivariable model). An inverse association between the lifestyle score and BCIS risk was observed in study centers, where participants were recruited mainly via mammographic screening and attended additional screening throughout follow-up (HR = 0.85, 95% CI 0.73-0.99), but not in the remaining ones (HR = 0.99, 95% CI 0.94-1.05). Conclusions: While we did not observe an overall association between lifestyle and BCIS risk, our results indicate that lifestyle is associated with BCIS risk among women recruited via screening programs and with regular screening participation. This suggests that a true inverse association between lifestyle habits and BCIS risk in the overall cohort may have been masked by a lack of information on screening attendance. The potential inverse association between lifestyle and BCIS risk in our analyses is consistent with the inverse associations between lifestyle scores and breast cancer risk reported from previous studies. © 2019 The Author(s).
- Published
- 2019
25. Antibody responses to Fusobacterium nucleatum Proteins in prediagnostic blood samples are not associated with risk of developing colorectal cancer
- Author
-
Butt, J., Jenab, M., Pawlita, M., Overvad, K., Tjonneland, A., Olsen, A., Boutron-Ruault, M.-C., Carbonnel, F., Mancini, F.R., Kaaks, R., Kuhn, T., Boeing, H., Trichopoulou, A., Karakatsani, A., Palli, D., Pala, V.M., Tumino, R., Sacerdote, C., Panico, S., Bueno-De-Mesquita, B., Van Gils, C.H., Vermeulen, R.C.H., Weiderpass, E., Quiros, J.R., Duell, E.J., Sanchez, M.-J., Dorronsoro, M., Huerta, J.M., Ardanaz, E., Van Guelpen, B., Harlid, S., Perez-Cornago, A., Gunter, M.J., Murphy, N., Freisling, H., Aune, D., Waterboer, T., Hughes, D.J., Butt, J., Jenab, M., Pawlita, M., Overvad, K., Tjonneland, A., Olsen, A., Boutron-Ruault, M.-C., Carbonnel, F., Mancini, F.R., Kaaks, R., Kuhn, T., Boeing, H., Trichopoulou, A., Karakatsani, A., Palli, D., Pala, V.M., Tumino, R., Sacerdote, C., Panico, S., Bueno-De-Mesquita, B., Van Gils, C.H., Vermeulen, R.C.H., Weiderpass, E., Quiros, J.R., Duell, E.J., Sanchez, M.-J., Dorronsoro, M., Huerta, J.M., Ardanaz, E., Van Guelpen, B., Harlid, S., Perez-Cornago, A., Gunter, M.J., Murphy, N., Freisling, H., Aune, D., Waterboer, T., and Hughes, D.J.
- Published
- 2019
26. Receptor activator of nuclear factor kB ligand, osteoprotegerin, and risk of death following a breast cancer diagnosis: Results from the EPIC cohort
- Author
-
Sarink, D. Schock, H. Johnson, T. Chang-Claude, J. Overvad, K. Olsen, A. Tjønneland, A. Arveux, P. Fournier, A. Kvaskoff, M. Boeing, H. Karakatsani, A. Trichopoulou, A. La Vecchia, C. Masala, G. Agnoli, C. Panico, S. Tumino, R. Sacerdote, C. Van Gils, C.H. Peeters, P.H.M. Weiderpass, E. Agudo, A. Rodríguez-Barranco, M. Huerta, J.M. Ardanaz, E. Gil, L. Kaw, K.T. Schmidt, J.A. Dossus, L. His, M. Aune, D. Riboli, E. Kaaks, R. Fortner, R.T.
- Subjects
musculoskeletal diseases - Abstract
Background: Receptor activator of nuclear factor kappa-B (RANK)-signaling is involved in tumor growth and spread in experimental models. Binding of RANK ligand (RANKL) to RANK activates signaling, which is inhibited by osteoprotegerin (OPG). We have previously shown that circulating soluble RANKL (sRANKL) and OPG are associated with breast cancer risk. Here we extend these findings to provide the first data on pre-diagnosis concentrations of sRANKL and OPG and risk of breast cancer-specific and overall mortality after a breast cancer diagnosis. Methods: Two thousand six pre- and postmenopausal women with incident invasive breast cancer (1620 (81%) with ER+ disease) participating in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort were followed-up for mortality. Pre-diagnosis concentrations of sRANKL and OPG were quantified in baseline serum samples using an enzyme-linked immunosorbent assay and electrochemiluminescent assay, respectively. Hazard ratios (HRs) and 95% confidence intervals (CIs) for breast cancer-specific and overall mortality were calculated using Cox proportional hazards regression models. Results: Especially in women with ER+ disease, higher circulating OPG concentrations were associated with higher risk of breast cancer-specific (quintile 5 vs 1 HR 1.77 [CI 1.03, 3.04]; ptrend 0.10) and overall mortality (q5 vs 1 HR 1.39 [CI 0.94, 2.05]; ptrend 0.02). sRANKL and the sRANKL/OPG ratio were not associated with mortality following a breast cancer diagnosis. Conclusions: High pre-diagnosis endogenous concentrations of OPG, the decoy receptor for RANKL, were associated with increased risk of death after a breast cancer diagnosis, especially in those with ER+ disease. These results need to be confirmed in well-characterized patient cohorts. © 2018 The Author(s).
- Published
- 2018
27. Defining the physiological miRNA landscape in nipple aspirate fluid
- Author
-
Patuleia, S.I.S., primary, Moelans, C.B., additional, van Gils, C.H., additional, van Diest, P.J., additional, and van der Wall, E., additional
- Published
- 2019
- Full Text
- View/download PDF
28. Circulating RANKL and RANKL/OPG and breast cancer risk by ER and PR subtype: Results from the EPIC cohort
- Author
-
Sarink, D. Schock, H. Johnson, T. Overvad, K. Holm, M. Tjønneland, A. Boutron-Ruault, M.-C. His, M. Kvaskoff, M. Boeing, H. Lagiou, P. Papatesta, E.-M. Trichopoulou, A. Palli, D. Pala, V. Mattiello, A. Tumino, R. Sacerdote, C. Bueno-De-Mesquita, H.B. Van Gils, C.H. Peeters, P.H. Weiderpass, E. Agudo, A. Sánchez, M.-J. Chirlaque, M.-D. Ardanaz, E. Amiano, P. Khaw, K.T. Travis, R. Dossus, L. Gunter, M. Rinaldi, S. Merritt, M. Riboli, E. Kaaks, R. Fortner, R.T.
- Abstract
Receptor activator of nuclear factor-kappa B (RANK)-RANK ligand (RANKL) signaling promotes mammary tumor development in experimental models. Circulating concentrations of soluble RANKL (sRANKL) may influence breast cancer risk via activation of RANK signaling; this may be modulated by osteoprotegerin (OPG), the decoy receptor for RANKL. sRANKL and breast cancer risk by hormone receptor subtype has not previously been investigated. A case-control study was nested in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. This study included 1, 976 incident invasive breast cancer cases [estrogen receptor positive (ER+), n=1, 598], matched 1:1 to controls. Women were pre- or postmenopausal at blood collection. Serum sRANKL was quantified using an ELISA, serum OPG using an electrochemiluminescent assay. Risk ratios (RR) and95% confidence intervals (95% CI) were calculated using conditional logistic regression. Associations between sRANKL and breast cancer risk differed by tumor hormone receptor status (Phet = 0.05). Higher concentrations of sRANKL were positively associated with risk of ER+ breast cancer [5th vs. 1st quintile RR 1.28 (95% CI, 1.01-1.63); Ptrend=0.20], but not ER-disease. For both ER+and estrogen and progesterone receptor positive (ER+PR+) breast cancer, results considering the sRANKL/OPG ratio were similar to those for sRANKL; we observed a suggestive inverse association between the ratio and ER-PR-disease [5th vs. 1st quintile RR = 0.60 (0.31-1.14); Ptrend=0.03]. This study provides the first largescale prospective data on circulating sRANKLand breast cancer. We observed limited evidence for an association between sRANKLand breast cancer risk. Cancer Prev Res; 10(9); 525-34. © 2017 American Association for Cancer Research.
- Published
- 2017
29. Biomarkers of folate and vitamin B12 and breast cancer risk: report from the EPIC cohort
- Author
-
Matejcic, M. de Batlle, J. Ricci, C. Biessy, C. Perrier, F. Huybrechts, I. Weiderpass, E. Boutron-Ruault, M.C. Cadeau, C. His, M. Cox, D.G. Boeing, H. Fortner, R.T. Kaaks, R. Lagiou, P. Trichopoulou, A. Benetou, V. Tumino, R. Panico, S. Sieri, S. Palli, D. Ricceri, F. Bueno-de-Mesquita, H.B. Skeie, G. Amiano, P. Sánchez, M.J. Chirlaque, M.D. Barricarte, A. Quirós, J.R. Buckland, G. van Gils, C.H. Peeters, P.H. Key, T.J. Riboli, E. Gylling, B. Zeleniuch-Jacquotte, A. Gunter, M.J. Romieu, I. Chajès, V.
- Abstract
Epidemiological studies have reported inconsistent findings for the association between B vitamins and breast cancer (BC) risk. We investigated the relationship between biomarkers of folate and vitamin B12 and the risk of BC in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Plasma concentrations of folate and vitamin B12 were determined in 2,491 BC cases individually matched to 2,521 controls among women who provided baseline blood samples. Multivariable logistic regression models were used to estimate odds ratios by quartiles of either plasma B vitamin. Subgroup analyses by menopausal status, hormone receptor status of breast tumors (estrogen receptor [ER], progesterone receptor [PR] and human epidermal growth factor receptor 2 [HER2]), alcohol intake and MTHFR polymorphisms (677C > T and 1298A > C) were also performed. Plasma levels of folate and vitamin B12 were not significantly associated with the overall risk of BC or by hormone receptor status. A marginally positive association was found between vitamin B12 status and BC risk in women consuming above the median level of alcohol (ORQ4-Q1 = 1.26; 95% CI 1.00–1.58; Ptrend = 0.05). Vitamin B12 status was also positively associated with BC risk in women with plasma folate levels below the median value (ORQ4-Q1 = 1.29; 95% CI 1.02–1.62; Ptrend = 0.03). Overall, folate and vitamin B12 status was not clearly associated with BC risk in this prospective cohort study. However, potential interactions between vitamin B12 and alcohol or folate on the risk of BC deserve further investigation. © 2016 UICC
- Published
- 2017
30. Gezondheidsraad. Briefadvies Amendement DENSE-studie
- Author
-
van Delden, J.J.M., Gussekloo, J., Adang, E.M.M., Boere-Boonekamp, M.M., Cornel, M.C., Dondorp, W.J., Dute, J.C.J., van Gils, C.H., van Langen, I.M., Middelkoop, B.J.C., Ploem, M.C., Stiggelbout, M., van der Wilt, G.J., Berkhout-van der Meulen, M.K., Kleefkens, M.G., Clinical genetics, Public and occupational health, and EMGO - Quality of care
- Published
- 2015
31. Gezondheidsraad. Briefadvies Amendement bij de Maastricht Studie: CT van het onderbeen
- Author
-
Gussekloo, J., Adang, E.M.M., Boere-Boonekamp, M.M., Cornel, M.C., van Delden, J.J.M., Dondorp, W.J., Drewes, Y.M., van Gils, C.H., van Langen, I.M., Middelkoop, B.J.C., Ploem, M.C., Stiggelbout, M., and van der Wilt, G.J.
- Published
- 2015
32. Gezondheidsraad. Doorlichten doorgelicht: gepast gebruik van health checks
- Author
-
van Delden, J.J.M., Gussekloo, J., Adang, E.M.M., Boere-Boonekamp, M.M., Cornel, M.C., Dondorp, W.J., Dute, J.C.J., van Gils, C.H., van Langen, I.M., Middelkoop, B.J.C., Ploem, M.C., Stiggelbout, M., and van der Wilt, G.J.
- Published
- 2015
33. Gezondheidsraad. Wet op het bevolkingsonderzoek: onderzoek naar ontlastingstests in het bevolkingsonderzoek naar darmkanker
- Author
-
van Delden, J.J.M., Gussekloo, J., Adang, E.M.M., Boere-Boonekamp, M.M., Cornel, M.C., Dondorp, W.J., Dute, J.C.J., van Gils, C.H., van Langen, I.M., Middelkoop, B.J.C., Ploem, M.C., Stiggelbout, M., Verbeek, A.L.M., and van der Wilt, G.J.
- Published
- 2015
34. Gezondheidsraad. Wet op het bevolkingsonderzoek: prevalentie van maagdarmaandoeningen onderzocht met een videocapsule
- Author
-
Gussekloo, J., Adang, E.M.M., Boere-Boonekamp, M.M., Cornel, M.C., van Delden, J.J.M., Dondorp, W.J., Drewes, Y.M., van Gils, C.H., van Langen, I.M., Middelkoop, B.J.C., Ploem, M.C., Stiggelbout, M., van der Wilt, G.J., Clinical genetics, Public and occupational health, EMGO - Quality of care, Faculty of Religion and Theology, and EMGO+ - Quality of Care
- Published
- 2015
35. Gezondheidsraad. Wet op het bevolkingsonderzoek: Risicostratificatie op basis van familiair risico op darmkanker
- Author
-
van Delden, J.J.M., Gussekloo, J., Adang, E.M.M., Boere-Boonekamp, M.M., Cornel, M.C., Dondorp, W.J., Drewes, Y.M., van Gils, C.H., van Langen, I.M., Middelkoop, B.J.C., Ploem, M.C., Stiggelbout, M., van der Wilt, G.J., Faculty of Religion and Theology, EMGO+ - Quality of Care, Clinical genetics, Public and occupational health, and EMGO - Quality of care
- Published
- 2015
36. OC-0534: No decline in patient reported outcomes following radiotherapy for breast cancer patients ≥ 60 years
- Author
-
Charaghvandi, K.R., primary, Young-Afat, D.A., additional, Van Gils, C.H., additional, Gregorowitsch, M.L., additional, Van Asselen, B., additional, Van Vulpen, M., additional, Verkooijen, H.M., additional, and Van den Bongard, H.J.G.D., additional
- Published
- 2016
- Full Text
- View/download PDF
37. Wet op het bevolkingsonderzoek: darmkankerscreening met een camerapil
- Author
-
van Delden, J.J.M., Gussekloo, J., Adang, E.M.M., Boere-Boonekamp, M.M., Cornel, M.C., Dondorp, W.J., Dute, J.C.J., van Gils, C.H., ten Kate, L.P., van Langen, I.M., Middelkoop, B.J.C., Ploem, M.C., Stiggelbout, A.M., van Veen, W., Verbeek, A.L.M., van der Wilt, G.J., Clinical genetics, and EMGO - Quality of care
- Published
- 2013
38. Wet op het bevolkingsonderzoek: voortzetting proefbevolkingsonderzoek naar darmkanker
- Author
-
van Delden, J.J.M., Gussekloo, J., Adang, E.M.M., Boere-Boonekamp, M.M., Cornel, M.C., Dondorp, W.J., Dute, J.C.J., van Gils, C.H., ten Kate, L.P., van Langen, I.M., Middelkoop, B.J.C., Ploem, M.C., Stiggelbout, A.M., van Veen, W., Verbeek, A.L.M., and van der Wilt, G.J.
- Published
- 2013
39. Wet op het bevolkingsonderzoek: niet-invasieve prenatale test bij verhoogd risico op trisomie
- Author
-
van Delden, J.J.M., Gussekloo, J., Adang, E.M.M., Boere-Boonekamp, M.M., Cornel, M.C., Dondorp, W.J., Dute, J.C.J., van Gils, C.H., ten Kate, L.P., van Langen, I.M., Middelkoop, B.J.C., Ploem, M.C., van Veen, W., Verbeek, A.L.M., and van der Wilt, G.J.
- Published
- 2013
40. Wet op het bevolkingsonderzoek: de Maastricht Studie
- Author
-
van Delden, J.J.M., Gussekloo, J., Adang, E.M.M., Boere-Boonekamp, M.M., Cornel, M.C., Dondorp, W.J., Dute, J.C.J., van Gils, C.H., ten Kate, L.P., van Langen, I.M., Middelkoop, B.J.C., Ploem, M.C., van Veen, W., Verbeek, A.L.M., van der Wilt, G.J., Clinical genetics, and EMGO - Quality of care
- Published
- 2013
41. Wet op het bevolkingsonderzoek: landelijk bevolkingsonderzoek naar darmkanker
- Author
-
van Delden, J.J.M., Gussekloo, J., Adang, E.M.M., Boere-Boonekamp, M.M., Cornel, M.C., Dondorp, W.J., Dute, J.C.J., van Gils, C.H., ten Kate, L.P., van Langen, I.M., Middelkoop, B.J.C., Ploem, M.C., Stiggelbout, A.M., van Veen, W., Verbeek, A.L.M., van der Wilt, G.J., Clinical genetics, and EMGO - Quality of care
- Published
- 2013
42. Briefadvies Wet op het bevolkingsonderzoek: tussentijds advies over een pilot bevolkingsonderzoek naar darmkanker
- Author
-
van Delden, J.J.M., Gussekloo, J., Adang, E.M.M., Boere-Boonekamp, M.M., Cornel, M.C., Dondorp, W.J., Dute, J.C.J., van Gils, C.H., ten Kate, L.P., van Langen, I.M., Middelkoop, B.J.C., Ploem, M.C., van Veen, W., and van der Wilt, G.J.
- Published
- 2013
43. Wet op het bevolkingsonderzoek: kalkscore en kans op hart- en vaatziekten
- Author
-
van Delden, J.J.M., Gussekloo, J., Adang, E.M.M., Boere-Boonekamp, M.M., Dondorp, W.J., Dute, J.C.J., Cornel, M.C., van Gils, C.H., ten Kate, L.P., van Langen, I.M., Middelkoop, B.J.C., Ploem, M.C., van Veen, W., Verbeek, A.L.M., van der Wilt, G.J., Clinical genetics, and EMGO - Quality of care
- Published
- 2013
44. NIPT: dynamiek en ethiek van prenatale screening
- Author
-
van Delden, J.J.M., Gussekloo, J., Adang, E.M.M., Boere-Boonekamp, M.M., Cornel, M.C., Dondorp, W.J., Dute, J.C.J., van Gils, C.H., ten Kate, L.P., van Langen, I.M., Middelkoop, B.J.C., Ploem, M.C., Stiggelbout, A.M., van Veen, W., Verbeek, A.L.M., and van der Wilt, G.J.
- Published
- 2013
45. Wet bevolkingsonderzoek: mammografie standaard in twee richtingen
- Author
-
van Delden, J.J.M., Gussekloo, J., Adang, E.M.M., Boere-Boonekamp, M.M., Cornel, M.C., Dondorp, W.J., Dute, J.C.J., van Gils, C.H., ten Kate, L.P., van Langen, I.M., Middelkoop, B.J.C., Ploem, M.C., van Veen, W., Verbeek, A.L.M., and van der Wilt, G.J.
- Published
- 2013
46. Fruit and vegetable consumption and mortality: European prospective investigation into cancer and nutrition
- Author
-
Leenders, M., van der Sluijs, I., Ros, M.M., Boshuizen, H.C., Siersema, P.D., Ferrari, P., Weikert, C., Tjonneland, A., Olsen, A., Boutron-Ruault, M.C., Clavel-Chapelon, F., Nailler, L., Teucher, B., Li, K.R., Boeing, H., Bergmann, M.M., Trichopoulou, A., Lagiou, P., Trichopoulos, D., Palli, D., Pala, V., Panico, S., Tumino, R., Sacerdote, C., Peeters, P.H.M., van Gils, C.H., Lund, E., Engeset, D., Redondo, M.L., Agudo, A., Sanchez, M.J., Navarro, C., Ardanaz, E., Sonestedt, E., Ericson, U., Nilsson, L.M., Khaw, K.T., Warcham, N.J., Key, T.J., Crowe, F.L., Romieu, I., Gunter, M.J., Gallo, V., Overvad, K., Riboli, E., Bueno-de-Mesquita, H.B., Leenders, M, Sluijs, I, Ros, Mm, Boshuizen, Hc, Siersema, Pd, Ferrari, P, Weikert, C, Tj?nneland, A, Olsen, A, Boutron Ruault, Mc, Clavel Chapelon, F, Nailler, L, Teucher, B, Li, K, Boeing, H, Bergmann, Mm, Trichopoulou, A, Lagiou, P, Trichopoulos, D, Palli, D, Pala, V, Panico, Salvatore, Tumino, R, Sacerdote, C, Peeters, Ph, van Gils, Ch, Lund, E, Engeset, D, Redondo, Ml, Agudo, A, S?nchez, Mj, Navarro, C, Ardanaz, E, Sonestedt, E, Ericson, U, Nilsson, Lm, Khaw, Kt, Wareham, Nj, Key, Tj, Crowe, Fl, Romieu, I, Gunter, Mj, Gallo, V, Overvad, K, Riboli, E, and Bueno de Mesquita, Hb
- Subjects
Adult ,Male ,Nutrition and Disease ,cardiovascular-disease ,men ,population ,Diet Surveys ,Wiskundige en Statistische Methoden - Biometris ,Cause of Death ,Neoplasms ,Voeding en Ziekte ,Vegetables ,Humans ,oxidative stress ,Prospective Studies ,Mathematical and Statistical Methods - Biometris ,Aged ,Proportional Hazards Models ,risk ,Molecular epidemiology Aetiology, screening and detection [NCEBP 1] ,dietary assessment ,health ,Middle Aged ,PE&RC ,calibration ,Survival Analysis ,heart-disease ,Europe ,Fruit ,impact ,Female - Abstract
In this study, the relation between fruit and vegetable consumption and mortality was investigated within the European Prospective Investigation Into Cancer and Nutrition. Survival analyses were performed, including 451,151 participants from 10 European countries, recruited between 1992 and 2000 and followed until 2010. Hazard ratios, rate advancement periods, and preventable proportions to respectively compare risk of death between quartiles of consumption, to estimate the period by which the risk of death was postponed among high consumers, and to estimate proportions of deaths that could be prevented if all participants would shift their consumption 1 quartile upward. Consumption of fruits and vegetables was inversely associated with all-cause mortality (for the highest quartile, hazard ratio = 0.90, 95% confidence interval (CI): 0.86, 0.94), with a rate advancement period of 1.12 years (95% CI: 0.70, 1.54), and with a preventable proportion of 2.95%. This association was driven mainly by cardiovascular disease mortality (for the highest quartile, hazard ratio = 0.85, 95% CI: 0.77, 0.93). Stronger inverse associations were observed for participants with high alcohol consumption or high body mass index and suggested in smokers. Inverse associations were stronger for raw than for cooked vegetable consumption. These results support the evidence that fruit and vegetable consumption is associated with a lower risk of death. In this study, the relation between fruit and vegetable consumption and mortality was investigated within the European Prospective Investigation Into Cancer and Nutrition. Survival analyses were performed, including 451,151 participants from 10 European countries, recruited between 1992 and 2000 and followed until 2010. Hazard ratios, rate advancement periods, and preventable proportions to respectively compare risk of death between quartiles of consumption, to estimate the period by which the risk of death was postponed among high consumers, and to estimate proportions of deaths that could be prevented if all participants would shift their consumption 1 quartile upward. Consumption of fruits and vegetables was inversely associated with all-cause mortality (for the highest quartile, hazard ratio = 0.90, 95% confidence interval (CI): 0.86, 0.94), with a rate advancement period of 1.12 years (95% CI: 0.70, 1.54), and with a preventable proportion of 2.95%. This association was driven mainly by cardiovascular disease mortality (for the highest quartile, hazard ratio = 0.85, 95% CI: 0.77, 0.93). Stronger inverse associations were observed for participants with high alcohol consumption or high body mass index and suggested in smokers. Inverse associations were stronger for raw than for cooked vegetable consumption. These results support the evidence that fruit and vegetable consumption is associated with a lower risk of death.
- Published
- 2013
47. Search for Breast Cancer Biomarkers in Fractionated Serum Samples by Protein Profiling With SELDI-TOF MS
- Author
-
Opstal - van Winden, A.W.J., Beijnen, J.H., de Loof, A., van Heerde, W.L., Vermeulen, R., Peeters, P.H.M., van Gils, C.H., Clinical Pharmacology, Risk Assessment of Toxic and Immunomodulatory Agents, Dep IRAS, and Sub Clinical Pharmacology
- Abstract
BackgroundMany high-abundant acute phase reactants have been previously detected as potential breast cancer biomar-kers. However, they are unlikely to be specific for breast cancer. Cancer-specific biomarkers are thought to be among the lower abundant proteins.MethodsWe aimed to detect lower abundant discriminating proteins by performing serum fractionation by strong anion exchange chromatography preceding protein profiling with SELDI-TOF MS. In a pilot study, we tested the different fractions resulting from fractionation, on several array types. Fraction 3 on IMAC30 and Fraction 6 on Q10 yielded the most discriminative proteins and were used for serum protein profiling of 73 incident breast cancer cases and 73 matched controls.ResultsEight peaks showed statistically significantly different intensities between cases and controls (P⧁0.05), and had less than 10% chance to be a false-positive finding. Seven of these were tentatively identified as apolipoprotein C-II (m/z 8,909), oxidized apolipoprotein C-II (m/z 8,925), apolipoprotein C-III (m/z 8,746), fragment of coagulation factor XIIIa (m/z 3,959), heterodimer of apolipoprotein A-I and apolipoprotein A-II (m/z 45,435), hemoglobin B-chain (m/z 15,915), and post-translational modified hemoglobin (m/z 15,346).ConclusionBy extensive serum fractionation, we detected many more proteins than in previous studies without fractionation. However, discriminating proteins were still high abundant. Results indicate that either lower abundant proteins are less distinctive, or more rigorous fractionation and selective protein depletion, or a more sensitive assay, are needed to detect lower abundant discriminative proteins.
- Published
- 2012
48. Plasma cotinine levels and pancreatic cancer in the EPIC cohort study
- Author
-
Leenders, M. Chuang, S.-C. Dahm, C.C. Overvad, K. Ueland, P.M. Midttun, O. Vollset, S.E. Tjønneland, A. Halkjær, J. Jenab, M. Clavel-Chapelon, F. Boutron-Ruault, M.-C. Kaaks, R. Canzian, F. Boeing, H. Weikert, C. Trichopoulou, A. Bamia, C. Naska, A. Palli, D. Pala, V. Mattiello, A. Tumino, R. Sacerdote, C. Van Duijnhoven, F.J.B. Peeters, P.H.M. Van Gils, C.H. Lund, E. Rodriguez, L. Duell, E.J. Pérez, M.-J.S. Molina-Montes, E. Castaño, J.M.H. Barricarte, A. Larrañaga, N. Johansen, D. Lindkvist, B. Sund, M. Ye, W. Khaw, K.-T. Wareham, N.J. Michaud, D.S. Riboli, E. Xun, W.W. Allen, N.E. Crowe, F.L. Bueno-De-Mesquita, H.B. Vineis, P.
- Abstract
Smoking is an established risk factor for pancreatic cancer, previously investigated by the means of questionnaires. Using cotinine as a biomarker for tobacco exposure allows more accurate quantitative analyses to be performed. This study on pancreatic cancer, nested within the European Prospective Investigation into Cancer and Nutrition (EPIC cohort), included 146 cases and 146 matched controls. Using liquid chromatography-mass spectrometry, plasma cotinine levels were analyzed on average 8.0 years before cancer onset (5-95% range: 2.8-12.0 years). The relation between plasma cotinine levels and pancreatic cancer was analyzed with conditional logistic regression for different levels of cotinine in a population of never and current smokers. This was also done for the self-reported number of smoked cigarettes per day at baseline. Every increase of 350 nmol/L of plasma cotinine was found to significantly elevate risk of pancreatic cancer [odds ratio (OR): 1.33, 95% confidence interval (CI): 1.11-1.60]. People with a cotinine level over 1187.8 nmol/L, a level comparable to smoking 17 cigarettes per day, have an elevated risk of pancreatic cancer, compared to people with cotinine levels below 55 nmol/L (OR: 3.66, 95% CI: 1.44-9.26). The results for self-reported smoking at baseline also show an increased risk of pancreatic cancer from cigarette smoking based on questionnaire information. People who smoke more than 30 cigarettes per day showed the highest risk compared to never smokers (OR: 4.15, 95% CI: 1.02-16.42). This study is the first to show that plasma cotinine levels are strongly related to pancreatic cancer. Copyright © 2011 UICC.
- Published
- 2012
49. Prognostic value of estrogen receptor alpha and progesterone receptor conversion in distant breast cancer metastases
- Author
-
Hoefnagel, L.D.C., Moelans, C.B., Meijer, S.L., van Slooten, H.J., Wesseling, P., Wesseling, J., Westenend, PJ, Bart, J., Seldenrijk, C.A., Nagtegaal, I.D., Oudejans, J., van der Valk, P., van Gils, C.H., van der Wall, E.E., van Diest, P.J., Pathology, and CCA - Disease profiling
- Subjects
Translational research [ONCOL 3] ,Translational research Tissue engineering and pathology [ONCOL 3] - Abstract
Contains fulltext : 109187pub.pdf (Publisher’s version ) (Closed access) BACKGROUND: Changes in the receptor profile of primary breast cancers to their metastases (receptor conversion) have been described for the estrogen receptor alpha (ERalpha) and progesterone receptor (PR). The purpose of this study was to evaluate the impact of receptor conversion for ERalpha and PR on survival in a large group of distant non-bone breast cancer metastases. METHODS: Receptor conversion was studied by immunohistochemistry in a group of 233 metastatic breast cancer patients. Kaplan-Meier overall survival curves were plotted, and differences between the curves were analyzed by log-rank analysis. The additional prognostic value of conversion to established prognosticators was studied by Cox regression. RESULTS: Overall survival of patients showing conversion from positive to negative ERalpha or PR, or from negative to positive ERalpha or PR, or remaining receptor negative was comparable, and significantly worse than patients remaining receptor positive. ERalpha or PR receptor conversion from positive in the primary breast tumor to negative in distant metastases has independent negative prognostic value. CONCLUSIONS: ERalpha or PR receptor conversion from positive in the primary breast cancer to negative in distant metastases has negative prognostic value. Cancer 2012. (c) 2012 American Cancer Society.
- Published
- 2012
50. Variety in vegetable and fruit consumption and risk of bladder cancer in the European Prospective Investigation into Cancer and Nutrition
- Author
-
Büchner, F.L. Bueno-De-Mesquita, H.B. Ros, M.M. Kampman, E. Egevad, L. Overvad, K. Tjãnneland, A. Roswall, N. Clavel-Chapelon, F. Boutron-Ruault, M.-C. Touillaud, M. Kaaks, R. Chang-Claude, J. Boeing, H. Weikert, S. Trichopoulou, A. Naska, A. Benetou, V. Palli, D. Sieri, S. Vineis, P. Tumino, R. Panico, S. Van Duijnhoven, F.J.B. Peeters, P.H.M. Van Gils, C.H. Lund, E. Gram, I.T. Sánchez, M.-J. Jakszyn, P. Larrañaga, N. Ardanaz, E. Navarro, C. Rodríguez, L. Manjer, J. Ehrnström, R. Hallmans, G. Ljungberg, B. Key, T.J. Allen, N.E. Khaw, K.-T. Wareham, N. Slimani, N. Jenab, M. Boffetta, P. Kiemeney, L.A.L.M. Riboli, E.
- Abstract
Recent research does not show an association between fruit and vegetable consumption and bladder cancer risk. None of these studies investigated variety in fruit and vegetable consumption, which may capture different aspects of consumption. We investigated whether a varied consumption of vegetables and fruits is associated with bladder cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Detailed data on food consumption and complete follow-up for cancer incidence were available for 452,185 participants, who were recruited from ten European countries. After a mean follow-up of 8.7 years, 874 participants were diagnosed with bladder cancer. Diet diversity scores (DDSs) were used to quantify the variety in fruit and vegetable consumption. Multivariable Cox proportional hazard models were used to assess the effect of the DDSs on bladder cancer risk. There was no evidence of a statistically significant association between bladder cancer risk and any of the DDSs when these scores were considered as continuous covariates. However, the hazard ratio (HR) for the highest tertile of the DDS for combined fruit and vegetable consumption was marginally significant compared to the lowest (HR = 1.30, 95% confidence interval: 1.00-1.69, p-trend = 0.05). In EPIC, there is no clear association between a varied fruit and vegetable consumption and bladder cancer risk. This finding provides further evidence for the absence of any strong association between fruit and vegetable consumption as measured by a food frequency questionnaire and bladder cancer risk. © 2010 UICC.
- Published
- 2011
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.